The 9 most recent market catalysts affecting $HCM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, HUTCHMED To Showcase New And Updated Clinical Data From Sponsored And Investigator-Initiated Studies Across Multiple Cancer Types At ESMO Congress 2026, Madrid
This headline signals a significant future event for HUTCHMED (HCM) as they prepare to unveil new and updated clinical data at a major oncology conference. The impact score is high…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 85
HUTCHMED shares are trading higher after the company announced entered into an exclusive development and license agreement that granted the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.
This headline represents a significant positive catalyst for HUTCHMED. The exclusive development and license agreement with GSK, a major pharmaceutical player, validates HUTCHMED's…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 85
HUTCHMED Signs GSK Cancer Drug Deal Worth Up To $1.3B, Gets $110M Upfront
HUTCHMED has secured a major licensing agreement with GSK for its HMPL-A830 cancer drug candidate, involving a substantial upfront payment and significant potential milestone payme…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
Reported Earlier, HUTCHMED Reports Late-Stage Results For New Lung Cancer Treatment Combo
HUTCHMED reported positive high-level results from its SANOVO China Phase III trial for a new lung cancer treatment combination (ORPATHYS® + TAGRISSO®). The trial demonstrated stat…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, HUTCHMED Gains China Approval For ATLED (Fanregratinib) As Confirmatory Phase IIIb Trial Enrollment Continues For FGFR2-Positive Cholangiocarcinoma
This headline is a significant positive catalyst for HUTCHMED (HCM) as it secures market access for ATLED in China, a major pharmaceutical market. This approval provides a new reve…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 85
HUTCHMED shares are trading higher after the company announced high-level results from the SAFFRON Phase III trial.
The announcement of high-level positive Phase III trial results is a major corporate catalyst for HUTCHMED. Successful late-stage clinical trials significantly de-risk a drug candi…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Sunday, HUTCHMED Says ORPATHYS Plus TAGRISSO Achieved Statistically Significant, Clinically Meaningful PFS And OS Improvements In MET-Driven EGFR-Mutated Lung Cancer
HUTCHMED reported that its ORPATHYS, when combined with AstraZeneca's TAGRISSO, achieved statistically significant and clinically meaningful progression-free survival (PFS) and ove…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 92
HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY
HUTCHMED (China) reported a dramatic 96.55% year-over-year decline in its H1 EPS, falling from $2.61 to $0.09. This sharp drop in profitability is a major concern for investors, es…
Jul 23, 2026
Corporate Catalyst
Bearish
Impact 55
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14
Goldman Sachs analyst Paul Choi maintained a 'Neutral' rating on HUTCHMED (China) but reduced the price target from $16 to $14. This action signals a slightly diminished valuation …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.